Does SummaCare Cover Metformin?

What SummaCare Is and How Its Formulary Works

SummaCare is a nonprofit health plan based in Akron, Ohio, operating as a subsidiary of Summa Health System. It offers Medicare Advantage, Medicare Supplement, and commercial plans to members primarily in northeast Ohio. Like all insurers, SummaCare publishes an annual formulary, a tiered drug list that determines what members pay at the pharmacy counter.

Formulary Tier Structure

SummaCare uses a tiered formulary system common to most Part D and commercial plans. Generic drugs such as metformin typically land on Tier 1 (preferred generic) or Tier 2 (non-preferred generic), carrying the lowest co-pays. Brand-name drugs occupy Tier 3 or higher, with substantially higher out-of-pocket costs.

The FDA approved metformin hydrochloride as a standalone agent for type 2 diabetes, and it appears on the formularies of more than 95% of Medicare Part D plans nationally, according to CMS formulary data. SummaCare's specific formulary documents are published annually and members should verify current tier placement through SummaCare's online drug search tool or by calling the member services number on their insurance card.

How to Verify Your Specific Plan

SummaCare members should take three steps before filling a metformin prescription:

1. Log into the SummaCare member portal and use the formulary search tool.
2. Ask the prescribing physician's office to confirm the NDC (National Drug Code) used, since immediate-release and extended-release formulations may sit on different tiers.
3. Call the pharmacy benefits number on the insurance card to confirm co-pay amounts for the specific quantity prescribed.

Metformin: FDA Approval and Clinical Evidence

Metformin has been prescribed for type 2 diabetes in the United States since FDA approval in 1994. It is the first-line oral agent recommended by the American Diabetes Association (ADA) Standards of Medical Care and the American Association of Clinical Endocrinology (AACE) guidelines for newly diagnosed type 2 diabetes in the absence of contraindications. [1]

Mechanism of Action

Metformin works primarily by suppressing hepatic glucose production through activation of AMP-activated protein kinase (AMPK). [2] Secondary effects include improved peripheral insulin sensitivity and modest reductions in intestinal glucose absorption. Unlike sulfonylureas, metformin does not stimulate pancreatic insulin secretion, so the risk of hypoglycemia when used as monotherapy is very low.

Landmark Clinical Evidence

The UK Prospective Diabetes Study 34 (UKPDS 34, N=1,704) compared metformin with conventional diet therapy in overweight patients with newly diagnosed type 2 diabetes. Metformin produced a 36% reduction in all-cause mortality (P<0.0001), a 39% reduction in myocardial infarction risk, and a 32% reduction in diabetes-related endpoints over a median follow-up of 10.7 years. [3] These results, published in The Lancet in 1998, cemented metformin as the cornerstone of type 2 diabetes pharmacotherapy.

The Diabetes Prevention Program (DPP, N=3,234) showed that metformin 850 mg twice daily reduced the incidence of type 2 diabetes by 31% over 2.8 years compared with placebo in adults with impaired fasting glucose and impaired glucose tolerance. [4] Intensive lifestyle intervention reduced incidence by 58%, but metformin remained a meaningful pharmacological option, particularly in adults under age 60 with BMI <35 kg/m².

"Metformin is the preferred initial pharmacologic agent for the treatment of type 2 diabetes," states the ADA Standards of Medical Care in Diabetes, Section 9 (Pharmacologic Approaches to Glycemic Treatment). [1]

Approved Dosing Regimens

The FDA-approved dosing range for metformin immediate-release is 500 mg to 2,550 mg per day, given in two to three divided doses with meals to reduce gastrointestinal side effects. [5] Extended-release formulations (metformin ER or metformin XR) allow once-daily dosing and tend to cause less nausea, though the FDA recalled certain extended-release lots in 2020 due to elevated N-nitrosodimethylamine (NDMA) levels. Members prescribed extended-release formulations should verify current lot status through the FDA's drug recall database. [6]

Does SummaCare Specifically Cover Metformin for Type 2 Diabetes?

For FDA-approved type 2 diabetes management, SummaCare covers metformin without prior authorization on most plan types. The drug's generic status keeps it on the preferred tier, and the ACA's preventive care mandates do not directly apply here because metformin for T2DM treatment is a therapeutic agent rather than a purely preventive service.

Medicare Advantage Plans

SummaCare Medicare Advantage members are covered under Part D pharmacy benefits. The Centers for Medicare and Medicaid Services (CMS) classifies metformin as a protected-class drug for diabetes, meaning Part D plans must cover at least two drugs per diabetes formulary category. [7] SummaCare's Medicare Advantage plans have historically placed metformin on Tier 1 with a $0 to $5 co-pay for a 30-day supply at preferred pharmacies.

Commercial and Employer Plans

For commercial members, coverage depends on the specific plan purchased by the employer or individual. Ohio's state insurance commission requires that fully insured plans cover essential health benefits, which include prescription drugs. Metformin's generic status and clinical importance make it a standard inclusion. Members on high-deductible health plans (HDHPs) may pay the full negotiated price until the deductible is met, but the negotiated price for a 30-day supply of generic metformin 500 mg is typically $4 to $10 at major pharmacy chains.

Medicare Supplement Plans

Medicare Supplement (Medigap) plans sold by SummaCare do not include prescription drug coverage by default. Members who hold only a Medicare Supplement plan need to enroll in a separate Part D plan or a SummaCare Medicare Advantage plan with drug coverage to have metformin covered at the pharmacy counter.

Metformin for Off-Label Uses: Prediabetes, PCOS, and Longevity

SummaCare's formulary covers drugs based on FDA-approved indications by default. Off-label prescribing is legal, but insurance coverage for off-label uses is not guaranteed and often requires prior authorization supported by clinical documentation.

Prediabetes

The DPP trial established metformin's efficacy in preventing progression from prediabetes to type 2 diabetes, reducing incidence by 31% at 2.8 years. [4] The ADA recommends considering metformin for high-risk individuals with prediabetes, specifically those with BMI <35, age <60, or history of gestational diabetes. [1] Some SummaCare plans may cover this indication with a physician's letter of medical necessity, citing DPP data and ADA guidelines.

The DPP Outcomes Study (DPPOS) followed participants for up to 15 years and found that metformin continued to reduce diabetes incidence by 18% relative to placebo over the full observation period, with a particularly strong effect in women with a history of gestational diabetes (49% reduction). [8]

Polycystic Ovary Syndrome

Metformin is used off-label for polycystic ovary syndrome (PCOS) to improve insulin sensitivity and restore ovulatory cycles. A Cochrane systematic review (2017) covering 44 randomized controlled trials found that metformin improved ovulation rates and reduced androgen levels compared with placebo. [9] Coverage for this indication varies by plan; prior authorization is common.

Longevity and Anti-Aging Research

The Targeting Aging with Metformin (TAME) trial, funded by the National Institute on Aging (NIA), is enrolling 3,000 adults aged 65 to 79 across 14 US sites to test whether metformin 1,500 mg per day delays the onset of age-related chronic diseases including cardiovascular disease, cancer, cognitive decline, and death. [10] This trial is ongoing and is expected to report primary results around 2027.

Preclinical evidence suggests metformin activates AMPK and inhibits mTORC1, pathways associated with cellular senescence and autophagy regulation. [2] A large observational study published in Aging Cell (Bannister et al., 2014, N=78,241) found that type 2 diabetic patients on metformin monotherapy lived longer than matched non-diabetic controls not on metformin, with a hazard ratio of 0.85 (95% CI 0.81 to 0.90) for all-cause mortality. [11]

SummaCare is very unlikely to cover metformin specifically for longevity optimization in the absence of a diabetes or prediabetes diagnosis. The TAME trial has not yet produced primary outcomes data, and no major guideline body currently recommends metformin for healthy aging as a standalone indication. A prescribing physician can submit a prior authorization request with supporting literature, but approval is not assured.

Prior Authorization: When Is It Required?

Prior authorization (PA) for metformin in standard T2DM treatment is uncommon on SummaCare plans. However, PA may be triggered in these scenarios:

• The prescriber writes for extended-release formulations above standard quantities.
• The diagnosis code on the prescription does not match an FDA-approved indication (for example, ICD-10 E11 is T2DM; E66 is obesity without a diabetes diagnosis).
• The member is enrolled in a specialty drug management program where the plan requires step therapy through lifestyle intervention first.
• Off-label use for PCOS, prediabetes prevention, or longevity is the documented rationale.

How to Handle a Prior Authorization Denial

If SummaCare denies a PA request, the prescribing physician can file a clinical appeal within 60 days of the denial notice. The appeal should include the patient's diagnosis codes, relevant lab values (HbA1c, fasting glucose, OGTT results), a clinical summary citing trial data (UKPDS 34 [3] or DPP [4] as appropriate), and the physician's clinical rationale. A peer-to-peer review call with the SummaCare medical director can also be requested and often resolves denials at a higher rate than written appeals alone.

Metformin Safety Profile and Contraindications

Metformin is generally well tolerated. The most common adverse effects are gastrointestinal: nausea, diarrhea, and abdominal cramping occur in up to 25% of patients initiating therapy. [5] These effects are dose-dependent and largely resolve within two to four weeks or with dose titration.

Lactic Acidosis Risk

The FDA's black-box warning for metformin addresses the risk of lactic acidosis, a rare but serious complication. [5] The absolute risk is approximately 3 cases per 100,000 patient-years based on a systematic review published in the Cochrane Database of Systematic Reviews (Salpeter et al., updated 2010). [12] The main contraindication is impaired renal function: metformin is contraindicated when the estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m². Dose reductions are recommended when eGFR is 30 to 45 mL/min/1.73 m².

Vitamin B12 Depletion

Long-term metformin use reduces vitamin B12 absorption in approximately 10 to 30% of patients by competing with intrinsic factor in the ileum. [13] The ADA recommends periodic B12 level monitoring in patients on long-term metformin, particularly those with peripheral neuropathy or anemia. Annual serum B12 measurement is a reasonable clinical practice.

Drug Interactions

Metformin interacts with iodinated contrast media: the FDA recommends holding metformin at the time of or before contrast-enhanced imaging procedures in patients with eGFR <60 mL/min/1.73 m², then reassessing renal function 48 hours post-procedure before restarting. [5]

Cost of Metformin Without Insurance

If SummaCare does not cover metformin or coverage is delayed during a PA review, members can access generic metformin at very low cash prices.

Retail and Discount Options

• GoodRx and similar discount platforms list 60 tablets of metformin 500 mg at $4 to $8 at most major pharmacy chains.
• Walmart's $4 generic drug program includes metformin immediate-release.
• Mark Cuban's Cost Plus Drugs (CostPlusDrugs.com) lists metformin 500 mg (90 tablets) at approximately $5 plus a $3 dispensing fee.

These prices apply to the immediate-release formulation. Extended-release generic metformin typically costs $8 to $20 per 30-day supply without insurance, depending on the dose and pharmacy.

Patient Assistance Programs

Major manufacturers and pharmacy retailers offer patient assistance for members who cannot afford even generic co-pays. The NeedyMeds database (needymeds.org) lists current programs by drug name. For members in a high-deductible plan year with an outstanding deductible, it may be less expensive to purchase metformin via a discount platform than to run it through insurance until the deductible is satisfied.

What Physicians at HealthRX Recommend for SummaCare Members

When evaluating metformin coverage with SummaCare, the prescribing physician's documentation carries more weight than any other factor in determining whether the pharmacy fills the prescription without issue. The ICD-10 code on the prescription must match the clinical indication, and the dose must be within the FDA-approved range for that indication to avoid an automatic PA trigger.

For patients seeking metformin for prediabetes or PCOS, the physician should document:

1. Relevant lab values (HbA1c 5.7% to 6.4% for prediabetes; elevated androgens and ultrasound findings for PCOS).
2. Prior lifestyle interventions attempted.
3. ADA or AACE guideline language supporting the use. [1]
4. The specific clinical benefit anticipated and the monitoring plan.

For longevity-focused use without a diabetes diagnosis, the current evidence base does not yet support routine coverage approval. The TAME trial results, expected around 2027, may change this. Until primary data are available, most insurers including SummaCare will treat this as investigational.

Comparing Metformin to Newer Diabetes Drugs on SummaCare Formularies

Metformin remains the least expensive and most accessible oral diabetes drug on virtually all formularies. Newer agents such as GLP-1 receptor agonists (semaglutide, tirzepatide) and SGLT-2 inhibitors (empagliflozin, dapagliflozin) have added cardiovascular and renal outcome benefits demonstrated in dedicated trials. [14] However, these agents sit on Tier 3 or Tier 4 of most SummaCare formularies, carry co-pays of $50 to $150 per month even with coverage, and often require step therapy through metformin first.

The ADA's Standards of Medical Care recommend metformin as the initial agent for most patients, with GLP-1 agonists or SGLT-2 inhibitors added in patients who have established cardiovascular disease, heart failure, or chronic kidney disease regardless of HbA1c. [1] This guideline sequence means that for most newly diagnosed SummaCare members, metformin coverage is the first formulary question, and it is one that most plans answer with a Tier 1 placement.

The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% and heart failure hospitalization by 35% compared with placebo in patients with established cardiovascular disease. [14] Results like this have shifted clinical practice for high-risk patients, but they do not displace metformin as the initial background therapy for newly diagnosed patients without these comorbidities.

Monitoring Requirements for Metformin Users

SummaCare plans may require periodic lab documentation to continue approving metformin fills under managed care programs. Standard clinical monitoring for patients on metformin includes:

• HbA1c: every three months until stable at goal, then every six months. [1]
• eGFR / serum creatinine: at baseline, then at least annually; more frequently if eGFR is 30 to 60 mL/min/1.73 m². [5]
• Serum B12: annually in patients on metformin for more than four years or those with neuropathy symptoms. [13]
• Liver function tests: not routinely required, but baseline LFTs are reasonable given metformin is predominantly renally cleared.

The National Kidney Foundation's KDIGO 2022 guideline on diabetes management in chronic kidney disease provides specific dose adjustment thresholds that align with the FDA label. [15]